Abstract
Improving infectious disease models plays a crucial role in mitigating global health impacts. Population-level models have been essential for understanding and anticipating impacts of infectious diseases, but their accuracy has often been limited due to changing environments, rapid pathogen evolution, and insufficient access to detailed transmission data. In particular, due to the lack of granular transmission data, many epidemiological models assume homogeneous disease transmission rather than acknowledge differences between groups within the host population. To address this gap, we conducted a simulation study to assess the potential for inferring group-structured viral transmission dynamics from phylogenetic data and to demonstrate how age structure can be incorporated in case projections. Using a synthetic dataset of 800 age-structured viral phylogenies and their associated case time series, we estimated transmission rates within and between age groups. Our results show that the estimates derived from phylogenies are more accurate than those from case counts alone, although both approaches enabled recovery of age-specific transmission differences. These results suggest that viral phylogenies and case-count time series each provide valuable data that can improve our understanding of population-level disease dynamics, ultimately contributing to more accurate and effective models for informing public policy and reducing disease burden.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research presented in this article was supported by the Laboratory Directed Research and Development program of Los Alamos National Laboratory under project number 20240066DR.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
8 Data Availability
Data and workflows for this study are generated from code publicly available in the repository at https://github.com/lanl/precog/tree/main/aim.